Science and Research

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

PURPOSE: In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small cell lung cancer (ES-SCLC). We report exploratory analyses of CASPIAN outcomes by programmed cell death ligand-1 (PD-L1) expression and tissue tumor mutational burden (tTMB). EXPERIMENTAL DESIGN: Patients were randomized (1:1:1) to durvalumab (1,500 mg) plus EP, durvalumab plus tremelimumab (75 mg) plus EP, or EP alone. Treatment effects in PD-L1 and tTMB subgroups were estimated using an unstratified Cox proportional hazards model. RESULTS: The PD-L1 and tTMB biomarker-evaluable populations (BEP) comprised 54.4% (438/805) and 35.2% (283/805) of the intention-to-treat population, respectively. PD-L1 prevalence was low: 5.7%, 25.8%, and 28.3% had PD-L1 expression on

  • Paz-Ares, L.
  • Garassino, M. C.
  • Chen, Y.
  • Reinmuth, N.
  • Hotta, K.
  • Poltoratskiy, A.
  • Trukhin, D.
  • Hochmair, M. J.
  • Özgüro
  • Ji, J. H.
  • Statsenko, G.
  • Conev, N.
  • Bondarenko, I.
  • Havel, L.
  • Losonczy, G.
  • Xie, M.
  • Lai, Z.
  • Godin-Heymann, N.
  • Mann, H.
  • Jiang, H.
  • Shrestha, Y.
  • Goldman, J. W.

Keywords

  • Humans
  • *Small Cell Lung Carcinoma/drug therapy/genetics
  • B7-H1 Antigen/genetics
  • Etoposide
  • Platinum
  • *Lung Neoplasms/drug therapy/genetics
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • *Antibodies, Monoclonal
  • *Antibodies, Monoclonal, Humanized
Publication details
DOI: 10.1158/1078-0432.Ccr-23-1689
Journal: Clin Cancer Res
Pages: 824-835 
Number: 4
Work Type: Original
Location: CPC-M
Disease Area: LC
Partner / Member: ASK
Access-Number: 37801329

DZL Engagements

chevron-down